Osteosarcoma Research Portal logoOsteosarcoma Research Portal

About osteosarcoma

Four short explainer videos, with the full narration as text below each one. Video 4 contains survival figures; you can skip it.

1. What is osteosarcoma?

Your bones might look solid, but inside they're alive. Every day, bone cells break down old bone and replace it with new bone.

Sometimes a few of those cells pick up changes in their genes and start growing in an uncontrolled, disorganised way. Over time, they form a lump called a tumour. This is osteosarcoma, a rare cancer that starts in the bone itself.

It can affect anyone, at any age. It's most common in teenagers and young adults, with a second, smaller peak in people over sixty. It's rare everywhere in the world.

It can start in any bone, but about seven in every ten begin in the long bones of the arms and legs, most often near the knee or the shoulder.

In most cases, nobody knows exactly why it happens. What we do know is that you can't catch it, and it isn't caused by anything you did.

This website is here to help with everything that comes next: what osteosarcoma does to the body, how it's treated, what the research says, and where it's heading. Every fact on it is checked against trusted sources.

I built this website because when I was going through treatment twenty years ago, there was limited information about this sort of thing, and I've had twenty years to reflect on things. My primary goal is to understand, and to get to a position where I know as much as I can about the advances in medicine to cure and prevent osteosarcoma, so that the next person who gets this in hospital has the best chance to survive it. This website is a tool for me to assess the direction of travel in drug and treatment development, but I think everyone else will be interested to see the findings too.

2. What it does to the body

When osteosarcoma grows in a bone, the body often sends messages that something isn't right. Here are the most common ones.

The main one is bone pain. It might come and go at first, then become more constant. It may be worse at night, and ordinary painkillers might not help much.

Some people notice swelling or a lump, if the tumour is close to the skin. A nearby joint might feel stiff or tender, or someone might start to limp. Occasionally, a bone weakened by the tumour can break without a big fall or knock.

Some people also feel unusually tired, lose weight, or have a high temperature.

Here's the important part. All of these things are much more often caused by everyday aches and injuries, and in older adults, bone pain is easily put down to arthritis. That's one reason osteosarcoma can take a while to spot. So noticing a symptom doesn't mean it's cancer. But pain that keeps going, or keeps coming back, is worth getting checked.

If doctors do find osteosarcoma, they'll want to know whether it has spread. When it spreads, the most common place is the lungs. That's why scans to check for spread are a normal part of the tests. Knowing this helps the team plan the right treatment.

3. Current treatments

Treatment for osteosarcoma is a journey, and nobody makes it alone. It's planned by a team of specialists: doctors, surgeons, nurses, physiotherapists and others. You'll usually have a specialist nurse, often called a key worker, to help along the way.

For the most common type, called high-grade osteosarcoma, treatment around the world usually combines two things: chemotherapy and surgery. Less common low-grade types are usually treated with surgery alone.

Chemotherapy, or chemo, uses medicines that travel through the whole body in the blood. It's usually given before surgery, to shrink the tumour, and again after surgery, to deal with any cancer cells left behind. For younger people, this often takes around thirty weeks. For older adults, doctors may use a different mix of medicines that's easier on the body. Chemo can cause side effects, like feeling sick, tiredness or hair loss, and these usually go after treatment finishes.

Surgery aims to remove the whole tumour. If it's in an arm or a leg, surgeons will try hard to save the limb, replacing the bone with a metal implant or a bone graft. Sometimes an amputation is the best choice, and specialists then help with a prosthetic, or artificial, limb.

Some younger patients may also be offered a medicine called mifamurtide. It is licensed in the European Union and recommended by NICE in the UK. It is not approved by the FDA in the United States, and it is not approved in China. Radiotherapy may be used if surgery isn't possible, and some people may be invited to join a clinical trial.

Afterwards, rehab helps you get strong and moving again, and regular check-ups continue for years.

4. Survival rates

This video talks about survival numbers. If you'd rather not hear them right now, that's completely okay. You can skip ahead, or come back another time.

Survival rates show how things went for large groups of people diagnosed years ago. They can't tell you what will happen to any one person.

In England, across all ages, almost sixty in every hundred people diagnosed between twenty fourteen and twenty sixteen were alive five years later.

Age makes a big difference. In the United States, for people diagnosed between twenty ten and twenty sixteen, about eight in ten children under ten were alive after five years. For ages ten to twenty-four it was about two in three, for ages twenty-five to fifty-nine just under six in ten, and for people over sixty fewer than four in ten.

Whether the cancer has spread matters too. When it's found before it spreads, about three in four people survive five years. When it has already spread, it's about one in four.

In clinical trials, where patients up to the age of forty were treated at specialist centres, about seven in ten were alive after five years.

Countries measure survival in different ways, over different years and age groups, so these numbers aren't a league table.

For young people, these numbers have barely moved since the nineteen nineties. That has to change. This website aims to draw attention to that, and to focus energy, attention and research on drug development, by bringing together the drugs in development in one portal.

Sources (footnote on screen with place, ages, years, measure): CRUK citing NCRAS (England 2014-16, net); Cole et al. Cancer 2022 doi:10.1002/cncr.34163 (SEER 2010-16, relative); ACS citing SEER 2012-18 (stage) ; Smeland et al. EJC 2019 doi:10.1016/j.ejca.2018.11.027 (EURAMOS-1, overall). Full tables: global_survival_research.md, all_ages_script_review.md.